Ignite Creation Date:
2025-12-25 @ 12:03 AM
Ignite Modification Date:
2025-12-25 @ 10:01 PM
Study NCT ID:
NCT01354158
Status:
COMPLETED
Last Update Posted:
2013-07-30
First Post:
2011-05-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Dose Titration of Droxidopa in Patients With Spinal Cord Injury
Sponsor:
Bronx VA Medical Center
Organization:
Study Overview
Official Title:
A Dose Response Trial of Droxidopa to Treat Hypotension in Persons With SCI
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators seek to determine the efficacy, duration of action and safety of escalating dose of droxidopa on systemic blood pressure, cerebral blood flow and vasoactive hormones and catecholamines during upright seated posture.
Primary Question:
1\. What is the lowest dose of droxidopa that increases seated SBP to 115±5 mmHg in men and 105±5 mmHg in women?
* When does the defined increase in SBP occur after oral ingestion of droxidopa?
* How long does this dose of droxidopa sustain SBP at these levels?
* What are the vital signs and the subjective symptomology following droxidopa administration?
Secondary Question:
1\. What is the MFV response to droxidopa administration in hypotensive individuals with SCI?
* Does an increase in SBP correspond to an increase in MCA MFV?
Tertiary Question:
1\. What is the vasoactive hormone and catecholamine response to droxidopa administration in hypotensive individuals with SCI?
* Does droxidopa administration result in a change in APR, Aldo or NE in hypotensive individuals with SCI?
Primary Question:
1\. What is the lowest dose of droxidopa that increases seated SBP to 115±5 mmHg in men and 105±5 mmHg in women?
* When does the defined increase in SBP occur after oral ingestion of droxidopa?
* How long does this dose of droxidopa sustain SBP at these levels?
* What are the vital signs and the subjective symptomology following droxidopa administration?
Secondary Question:
1\. What is the MFV response to droxidopa administration in hypotensive individuals with SCI?
* Does an increase in SBP correspond to an increase in MCA MFV?
Tertiary Question:
1\. What is the vasoactive hormone and catecholamine response to droxidopa administration in hypotensive individuals with SCI?
* Does droxidopa administration result in a change in APR, Aldo or NE in hypotensive individuals with SCI?
Detailed Description:
Persons with spinal cord injury (SCI), due to partial to complete interruption of sympathetic pathways from the brainstem to the cardiovascular system are prone to blood pressure dysregulation including hypotension which is worsened during orthostasis. It is well established that orthostatic hypotension (OH) hinders the rehabilitation process during the acute phase of SCI but also may hamper the resumption of independence and activity in persons with chronic SCI. Surprisingly, only a few reports exist on the use and efficacy of an alpha receptor agonist (midodrine hydrochloride) to restore blood pressure to more normal levels in persons with tetraplegia. Our group has recently reported normalization of supine blood pressure with a relatively low dose of the nitric oxide synthase inhibitor (NOSi), nitro-L-arginine methyl ester (L-NAME). In addition to an alpha agonist and a NOSi, the use of a norepinephrine (NE) precursor, droxidopa, may be safe and efficacious for the treatment of orthostatic hypotension in a human model of SCI.
It has been demonstrated that the blood pressure-raising effect of 3,4-threo-dihydroxyphenylserine (droxidopa) occurs independently of the central nervous system in human models of neurologic OH by conversion to norepinephrine (NE) in neuronal and non-neuronal tissue. Oral droxidopa is taken up by the more peripheral sympathetic neurons, converted to NE, stored and released appropriately during postural stress. Droxidopa has been used for the effective treatment of OH in several human models of neurologically caused autonomic disorders, such as familial amyloid polyneuropathy, autoimmune autonomic neuropathy, pure autonomic failure, and multiple system atrophy . The effectiveness of droxidopa at improving orthostatic blood pressure in persons with SCI has not been studied. To date, only a single case on the use of the drug in a person with SCI has been reported and the use droxidopa in that case was successful. The purpose of this proposal is to determine the dose effectiveness, duration of action and any adverse events following droxidopa administration in hypotensive individuals with SCI.
To determine the efficacy, duration of action and safety of escalating dose of droxidopa on systemic blood pressure, cerebral blood flow and vasoactive hormones and catecholamines during upright seated posture.
Primary Question:
1\. What is the lowest dose of droxidopa that increases seated SBP to 115±5 mmHg in men and 105±5 mmHg in women?
* When does the defined increase in SBP occur after oral ingestion of droxidopa?
* How long does this dose of droxidopa sustain SBP at these levels?
* What are the vital signs and the subjective symptomology following droxidopa administration?
Secondary Question:
1\. What is the MFV response to droxidopa administration in hypotensive individuals with SCI?
* Does an increase in SBP correspond to an increase in MCA MFV?
Tertiary Question:
1\. What is the vasoactive hormone and catecholamine response to droxidopa administration in hypotensive individuals with SCI?
* Does droxidopa administration result in a change in APR, Aldo or NE in hypotensive individuals with SCI?
It has been demonstrated that the blood pressure-raising effect of 3,4-threo-dihydroxyphenylserine (droxidopa) occurs independently of the central nervous system in human models of neurologic OH by conversion to norepinephrine (NE) in neuronal and non-neuronal tissue. Oral droxidopa is taken up by the more peripheral sympathetic neurons, converted to NE, stored and released appropriately during postural stress. Droxidopa has been used for the effective treatment of OH in several human models of neurologically caused autonomic disorders, such as familial amyloid polyneuropathy, autoimmune autonomic neuropathy, pure autonomic failure, and multiple system atrophy . The effectiveness of droxidopa at improving orthostatic blood pressure in persons with SCI has not been studied. To date, only a single case on the use of the drug in a person with SCI has been reported and the use droxidopa in that case was successful. The purpose of this proposal is to determine the dose effectiveness, duration of action and any adverse events following droxidopa administration in hypotensive individuals with SCI.
To determine the efficacy, duration of action and safety of escalating dose of droxidopa on systemic blood pressure, cerebral blood flow and vasoactive hormones and catecholamines during upright seated posture.
Primary Question:
1\. What is the lowest dose of droxidopa that increases seated SBP to 115±5 mmHg in men and 105±5 mmHg in women?
* When does the defined increase in SBP occur after oral ingestion of droxidopa?
* How long does this dose of droxidopa sustain SBP at these levels?
* What are the vital signs and the subjective symptomology following droxidopa administration?
Secondary Question:
1\. What is the MFV response to droxidopa administration in hypotensive individuals with SCI?
* Does an increase in SBP correspond to an increase in MCA MFV?
Tertiary Question:
1\. What is the vasoactive hormone and catecholamine response to droxidopa administration in hypotensive individuals with SCI?
* Does droxidopa administration result in a change in APR, Aldo or NE in hypotensive individuals with SCI?
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: